| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 70 | 2022 | 140 | 21.190 |
Why?
|
| Soft Tissue Neoplasms | 27 | 2022 | 53 | 8.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 37 | 2022 | 240 | 7.210 |
Why?
|
| Antineoplastic Agents | 29 | 2022 | 196 | 6.820 |
Why?
|
| Gastrointestinal Stromal Tumors | 22 | 2022 | 29 | 6.380 |
Why?
|
| Doxorubicin | 23 | 2021 | 57 | 5.260 |
Why?
|
| Biomarkers, Tumor | 19 | 2020 | 198 | 4.130 |
Why?
|
| Gastrointestinal Neoplasms | 10 | 2022 | 23 | 3.600 |
Why?
|
| Humans | 173 | 2022 | 22592 | 3.390 |
Why?
|
| Neoplasms | 10 | 2021 | 216 | 3.100 |
Why?
|
| Leiomyosarcoma | 13 | 2022 | 23 | 3.000 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 11 | 2021 | 11 | 2.830 |
Why?
|
| Liposarcoma | 13 | 2022 | 17 | 2.760 |
Why?
|
| Deoxycytidine | 8 | 2020 | 20 | 2.730 |
Why?
|
| Adult | 77 | 2022 | 6826 | 2.560 |
Why?
|
| Female | 103 | 2022 | 12734 | 2.470 |
Why?
|
| Middle Aged | 76 | 2021 | 7800 | 2.450 |
Why?
|
| Antineoplastic Agents, Alkylating | 11 | 2022 | 12 | 2.410 |
Why?
|
| Triazines | 7 | 2021 | 11 | 2.410 |
Why?
|
| Hemangiosarcoma | 5 | 2022 | 10 | 2.390 |
Why?
|
| Aged | 67 | 2022 | 7300 | 2.360 |
Why?
|
| Male | 83 | 2022 | 12260 | 2.320 |
Why?
|
| Antibodies, Monoclonal | 10 | 2022 | 163 | 2.320 |
Why?
|
| Medical Oncology | 4 | 2021 | 43 | 2.310 |
Why?
|
| Hemangioendothelioma, Epithelioid | 4 | 2022 | 5 | 2.240 |
Why?
|
| Antibiotics, Antineoplastic | 9 | 2021 | 17 | 2.190 |
Why?
|
| Neoadjuvant Therapy | 10 | 2021 | 61 | 2.130 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2020 | 17 | 1.960 |
Why?
|
| Treatment Outcome | 37 | 2021 | 2915 | 1.930 |
Why?
|
| Retrospective Studies | 42 | 2022 | 2954 | 1.890 |
Why?
|
| Mutation | 11 | 2022 | 327 | 1.850 |
Why?
|
| Tetrahydroisoquinolines | 8 | 2017 | 10 | 1.790 |
Why?
|
| Pyrroles | 6 | 2021 | 22 | 1.770 |
Why?
|
| Young Adult | 35 | 2021 | 1607 | 1.730 |
Why?
|
| Pyrazoles | 6 | 2021 | 58 | 1.680 |
Why?
|
| Prognosis | 31 | 2021 | 719 | 1.660 |
Why?
|
| Fibrosarcoma | 5 | 2020 | 9 | 1.650 |
Why?
|
| Sarcoma, Clear Cell | 3 | 2020 | 3 | 1.610 |
Why?
|
| Sarcoma, Synovial | 6 | 2019 | 11 | 1.580 |
Why?
|
| Breast Neoplasms | 16 | 2014 | 375 | 1.570 |
Why?
|
| Neoplasm Staging | 18 | 2021 | 344 | 1.560 |
Why?
|
| Survival Rate | 23 | 2021 | 302 | 1.480 |
Why?
|
| Retroperitoneal Neoplasms | 4 | 2022 | 7 | 1.450 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2022 | 55 | 1.440 |
Why?
|
| Dioxoles | 7 | 2017 | 12 | 1.370 |
Why?
|
| Aged, 80 and over | 32 | 2021 | 3657 | 1.330 |
Why?
|
| Chemotherapy, Adjuvant | 18 | 2022 | 80 | 1.330 |
Why?
|
| Osteosarcoma | 3 | 2021 | 35 | 1.330 |
Why?
|
| Molecular Targeted Therapy | 4 | 2018 | 31 | 1.290 |
Why?
|
| Adolescent | 26 | 2021 | 1855 | 1.270 |
Why?
|
| Quality of Life | 6 | 2021 | 557 | 1.240 |
Why?
|
| Bone Neoplasms | 3 | 2021 | 117 | 1.230 |
Why?
|
| Neoplasm Recurrence, Local | 12 | 2022 | 195 | 1.150 |
Why?
|
| Anthracyclines | 14 | 2020 | 17 | 1.140 |
Why?
|
| Disease Management | 9 | 2020 | 99 | 1.130 |
Why?
|
| Uterine Neoplasms | 4 | 2017 | 17 | 1.080 |
Why?
|
| Combined Modality Therapy | 12 | 2021 | 292 | 1.030 |
Why?
|
| Patient Satisfaction | 2 | 2020 | 255 | 1.030 |
Why?
|
| Ifosfamide | 6 | 2019 | 13 | 1.010 |
Why?
|
| Disease-Free Survival | 16 | 2021 | 168 | 1.000 |
Why?
|
| Prospective Studies | 15 | 2021 | 1476 | 0.990 |
Why?
|
| Proto-Oncogene Proteins c-kit | 9 | 2022 | 15 | 0.970 |
Why?
|
| Palliative Care | 3 | 2018 | 104 | 0.960 |
Why?
|
| Cardiotoxicity | 3 | 2021 | 8 | 0.910 |
Why?
|
| Exons | 3 | 2022 | 30 | 0.890 |
Why?
|
| Clinical Trials as Topic | 8 | 2021 | 189 | 0.830 |
Why?
|
| Pyrimidines | 7 | 2022 | 24 | 0.820 |
Why?
|
| Kaplan-Meier Estimate | 16 | 2021 | 165 | 0.820 |
Why?
|
| Fibromatosis, Aggressive | 6 | 2020 | 7 | 0.770 |
Why?
|
| Hemangioendothelioma | 1 | 2022 | 2 | 0.770 |
Why?
|
| Heart Diseases | 3 | 2008 | 58 | 0.760 |
Why?
|
| Imatinib Mesylate | 6 | 2022 | 8 | 0.760 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2022 | 83 | 0.760 |
Why?
|
| Immunotherapy | 3 | 2021 | 50 | 0.750 |
Why?
|
| Heart | 2 | 2021 | 59 | 0.740 |
Why?
|
| Follow-Up Studies | 14 | 2021 | 1403 | 0.730 |
Why?
|
| Furans | 3 | 2021 | 4 | 0.720 |
Why?
|
| Ketones | 3 | 2021 | 19 | 0.720 |
Why?
|
| Antigens, Neoplasm | 8 | 2020 | 40 | 0.710 |
Why?
|
| Cardiovascular Diseases | 3 | 2021 | 281 | 0.710 |
Why?
|
| Phosphoramide Mustards | 3 | 2019 | 3 | 0.690 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2020 | 6 | 0.680 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 15 | 0.680 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2020 | 15 | 0.670 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2020 | 12 | 0.670 |
Why?
|
| Genital Neoplasms, Female | 1 | 2020 | 15 | 0.660 |
Why?
|
| Workload | 1 | 2020 | 26 | 0.660 |
Why?
|
| Myoepithelioma | 2 | 2019 | 4 | 0.660 |
Why?
|
| Ovarian Neoplasms | 1 | 2021 | 78 | 0.660 |
Why?
|
| Nitroimidazoles | 2 | 2019 | 2 | 0.650 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2019 | 1 | 0.650 |
Why?
|
| Fibroma | 1 | 2020 | 5 | 0.640 |
Why?
|
| Ambulatory Care | 1 | 2020 | 65 | 0.640 |
Why?
|
| Dacarbazine | 6 | 2021 | 6 | 0.640 |
Why?
|
| Withholding Treatment | 1 | 2019 | 2 | 0.630 |
Why?
|
| Neoplasm Grading | 8 | 2020 | 47 | 0.630 |
Why?
|
| Pandemics | 2 | 2021 | 198 | 0.630 |
Why?
|
| Alanine | 1 | 2019 | 11 | 0.630 |
Why?
|
| Neoplasm Metastasis | 9 | 2021 | 99 | 0.620 |
Why?
|
| Cancer Vaccines | 4 | 2020 | 7 | 0.610 |
Why?
|
| Outpatients | 1 | 2019 | 54 | 0.600 |
Why?
|
| Immunohistochemistry | 12 | 2020 | 333 | 0.600 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 76 | 0.590 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 79 | 0.590 |
Why?
|
| Telemedicine | 1 | 2020 | 84 | 0.590 |
Why?
|
| Animals | 11 | 2021 | 3238 | 0.580 |
Why?
|
| Tertiary Care Centers | 2 | 2018 | 63 | 0.580 |
Why?
|
| Sulfonamides | 6 | 2022 | 45 | 0.580 |
Why?
|
| Inpatients | 1 | 2019 | 114 | 0.580 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 3 | 0.570 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2021 | 13 | 0.570 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 42 | 0.570 |
Why?
|
| Oncogene Proteins, Fusion | 6 | 2020 | 10 | 0.550 |
Why?
|
| Head and Neck Neoplasms | 2 | 2019 | 125 | 0.550 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 41 | 0.550 |
Why?
|
| Child | 10 | 2022 | 1148 | 0.540 |
Why?
|
| Survival Analysis | 9 | 2020 | 227 | 0.540 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2021 | 20 | 0.540 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2017 | 16 | 0.530 |
Why?
|
| T-Lymphocytes | 4 | 2021 | 93 | 0.510 |
Why?
|
| Receptors, Estrogen | 6 | 2010 | 62 | 0.500 |
Why?
|
| Liposarcoma, Myxoid | 4 | 2019 | 4 | 0.500 |
Why?
|
| Drug Repositioning | 1 | 2016 | 4 | 0.500 |
Why?
|
| Research Design | 2 | 2017 | 152 | 0.490 |
Why?
|
| General Surgery | 1 | 2016 | 50 | 0.490 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 529 | 0.460 |
Why?
|
| Phenylurea Compounds | 3 | 2021 | 5 | 0.450 |
Why?
|
| Pyrazines | 1 | 2014 | 12 | 0.450 |
Why?
|
| Naphthyridines | 4 | 2021 | 4 | 0.440 |
Why?
|
| Age Factors | 4 | 2021 | 623 | 0.440 |
Why?
|
| Urea | 4 | 2021 | 9 | 0.440 |
Why?
|
| Femur | 1 | 2016 | 294 | 0.440 |
Why?
|
| Ki-67 Antigen | 3 | 2009 | 18 | 0.430 |
Why?
|
| Imidazoles | 1 | 2014 | 62 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2017 | 242 | 0.420 |
Why?
|
| Double-Blind Method | 5 | 2022 | 371 | 0.420 |
Why?
|
| Sarcoma, Ewing | 1 | 2013 | 5 | 0.420 |
Why?
|
| Cardiotonic Agents | 2 | 2015 | 9 | 0.410 |
Why?
|
| Adenosarcoma | 1 | 2013 | 1 | 0.400 |
Why?
|
| Proportional Hazards Models | 5 | 2020 | 269 | 0.380 |
Why?
|
| Signal Transduction | 3 | 2021 | 393 | 0.380 |
Why?
|
| Indazoles | 6 | 2022 | 9 | 0.380 |
Why?
|
| Clinical Trials, Phase I as Topic | 3 | 2018 | 7 | 0.380 |
Why?
|
| Receptor, ErbB-2 | 5 | 2010 | 52 | 0.370 |
Why?
|
| Hydrazines | 2 | 2022 | 7 | 0.370 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2019 | 27 | 0.360 |
Why?
|
| Antibodies, Neutralizing | 2 | 2021 | 15 | 0.360 |
Why?
|
| Cohort Studies | 5 | 2020 | 1386 | 0.360 |
Why?
|
| Triazoles | 2 | 2022 | 29 | 0.360 |
Why?
|
| Ventricular Function, Left | 2 | 2021 | 32 | 0.350 |
Why?
|
| Pyridines | 2 | 2021 | 27 | 0.340 |
Why?
|
| Transcription Factor RelA | 1 | 2010 | 16 | 0.340 |
Why?
|
| Retreatment | 3 | 2020 | 8 | 0.330 |
Why?
|
| Precision Medicine | 2 | 2021 | 24 | 0.320 |
Why?
|
| Watchful Waiting | 2 | 2019 | 10 | 0.320 |
Why?
|
| Time Factors | 4 | 2021 | 1247 | 0.320 |
Why?
|
| Diagnosis, Differential | 6 | 2020 | 302 | 0.310 |
Why?
|
| Cell Proliferation | 2 | 2014 | 164 | 0.310 |
Why?
|
| Transcription Factors | 3 | 2020 | 149 | 0.310 |
Why?
|
| Disease Progression | 7 | 2021 | 517 | 0.310 |
Why?
|
| United Kingdom | 2 | 2020 | 27 | 0.310 |
Why?
|
| Risk Assessment | 4 | 2018 | 537 | 0.300 |
Why?
|
| Razoxane | 1 | 2008 | 1 | 0.300 |
Why?
|
| Biopsy | 5 | 2021 | 188 | 0.300 |
Why?
|
| Standard of Care | 2 | 2020 | 11 | 0.290 |
Why?
|
| Dendritic Cells | 2 | 2019 | 33 | 0.290 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 314 | 0.290 |
Why?
|
| Clinical Decision-Making | 2 | 2020 | 40 | 0.290 |
Why?
|
| Skin Neoplasms | 2 | 2020 | 67 | 0.280 |
Why?
|
| Antigens, CD | 2 | 2019 | 49 | 0.280 |
Why?
|
| Polyethylene Glycols | 3 | 2021 | 35 | 0.270 |
Why?
|
| Treatment Failure | 3 | 2017 | 123 | 0.270 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2017 | 36 | 0.270 |
Why?
|
| Neoplasm Invasiveness | 6 | 2014 | 84 | 0.260 |
Why?
|
| Neoplasms, Fibrous Tissue | 2 | 2020 | 2 | 0.260 |
Why?
|
| Rare Diseases | 2 | 2016 | 12 | 0.250 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2019 | 311 | 0.250 |
Why?
|
| Rhabdomyosarcoma | 2 | 2016 | 8 | 0.250 |
Why?
|
| Surveys and Questionnaires | 3 | 2020 | 1019 | 0.240 |
Why?
|
| Membrane Proteins | 4 | 2020 | 151 | 0.240 |
Why?
|
| RNA-Binding Protein EWS | 3 | 2020 | 4 | 0.230 |
Why?
|
| Cell Line, Tumor | 4 | 2021 | 242 | 0.230 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 17 | 0.230 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2005 | 8 | 0.230 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 13 | 0.230 |
Why?
|
| Benzamides | 2 | 2020 | 12 | 0.230 |
Why?
|
| Databases, Factual | 2 | 2018 | 300 | 0.230 |
Why?
|
| Metastasectomy | 2 | 2021 | 7 | 0.230 |
Why?
|
| Cardiomyopathies | 1 | 2005 | 23 | 0.220 |
Why?
|
| Myocardium | 1 | 2005 | 100 | 0.220 |
Why?
|
| Piperazines | 1 | 2005 | 81 | 0.220 |
Why?
|
| Neoplasms, Radiation-Induced | 2 | 2021 | 11 | 0.210 |
Why?
|
| Remission Induction | 3 | 2018 | 89 | 0.210 |
Why?
|
| Sirolimus | 2 | 2020 | 20 | 0.210 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 47 | 0.210 |
Why?
|
| DNA-Binding Proteins | 3 | 2018 | 224 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2017 | 130 | 0.200 |
Why?
|
| Multivariate Analysis | 2 | 2021 | 282 | 0.200 |
Why?
|
| Repressor Proteins | 2 | 2021 | 33 | 0.200 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2007 | 111 | 0.200 |
Why?
|
| Chemoradiotherapy | 2 | 2021 | 54 | 0.200 |
Why?
|
| Drug Administration Schedule | 6 | 2021 | 151 | 0.190 |
Why?
|
| Lentivirus | 2 | 2019 | 7 | 0.190 |
Why?
|
| Methotrexate | 2 | 2021 | 36 | 0.190 |
Why?
|
| Vinblastine | 3 | 2020 | 7 | 0.190 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 2 | 2019 | 2 | 0.190 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2019 | 13 | 0.190 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 119 | 0.190 |
Why?
|
| Dermatofibrosarcoma | 2 | 2016 | 3 | 0.190 |
Why?
|
| Genetic Vectors | 2 | 2019 | 55 | 0.190 |
Why?
|
| Biology | 1 | 2022 | 6 | 0.190 |
Why?
|
| Biological Products | 1 | 2022 | 31 | 0.180 |
Why?
|
| Neoplasm Seeding | 1 | 2021 | 8 | 0.180 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 11 | 0.180 |
Why?
|
| In Situ Hybridization | 5 | 2010 | 47 | 0.180 |
Why?
|
| Epirubicin | 2 | 2019 | 3 | 0.180 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2021 | 1 | 0.180 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 44 | 0.180 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2021 | 3 | 0.180 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2021 | 7 | 0.180 |
Why?
|
| Cancer Pain | 1 | 2021 | 3 | 0.180 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2021 | 45 | 0.180 |
Why?
|
| Esophagoscopy | 1 | 2021 | 15 | 0.180 |
Why?
|
| Stroke Volume | 1 | 2021 | 42 | 0.170 |
Why?
|
| Esophagectomy | 1 | 2021 | 22 | 0.170 |
Why?
|
| Margins of Excision | 4 | 2021 | 27 | 0.170 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2020 | 4 | 0.170 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2020 | 4 | 0.170 |
Why?
|
| Kidney Neoplasms | 1 | 2021 | 75 | 0.170 |
Why?
|
| SMARCB1 Protein | 1 | 2020 | 2 | 0.170 |
Why?
|
| Ligands | 1 | 2020 | 39 | 0.170 |
Why?
|
| Pyridones | 1 | 2020 | 9 | 0.170 |
Why?
|
| Macrophages | 1 | 2021 | 88 | 0.170 |
Why?
|
| Vulva | 1 | 2020 | 2 | 0.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 92 | 0.170 |
Why?
|
| Uterus | 1 | 2020 | 16 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 9 | 0.170 |
Why?
|
| Esophageal Neoplasms | 1 | 2021 | 47 | 0.170 |
Why?
|
| Cisplatin | 1 | 2021 | 60 | 0.170 |
Why?
|
| Smad3 Protein | 1 | 2020 | 1 | 0.170 |
Why?
|
| DNA Helicases | 1 | 2020 | 3 | 0.170 |
Why?
|
| Ovary | 1 | 2020 | 22 | 0.170 |
Why?
|
| Dermis | 1 | 2020 | 8 | 0.170 |
Why?
|
| Antigens, CD34 | 1 | 2020 | 12 | 0.170 |
Why?
|
| Calmodulin-Binding Proteins | 2 | 2017 | 3 | 0.170 |
Why?
|
| Mediastinal Neoplasms | 1 | 2020 | 9 | 0.170 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 70 | 0.170 |
Why?
|
| Vagina | 1 | 2020 | 31 | 0.170 |
Why?
|
| Travel | 1 | 2020 | 14 | 0.170 |
Why?
|
| Biomarkers | 2 | 2019 | 455 | 0.170 |
Why?
|
| Gene Amplification | 4 | 2010 | 21 | 0.160 |
Why?
|
| RNA-Binding Proteins | 2 | 2017 | 19 | 0.160 |
Why?
|
| Iliac Vein | 1 | 2020 | 3 | 0.160 |
Why?
|
| Vascular Neoplasms | 1 | 2020 | 4 | 0.160 |
Why?
|
| Vena Cava, Inferior | 1 | 2020 | 9 | 0.160 |
Why?
|
| Ribs | 1 | 2020 | 11 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 55 | 0.160 |
Why?
|
| Cyclin B | 1 | 2019 | 4 | 0.160 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 72 | 0.160 |
Why?
|
| Fibromatosis, Abdominal | 1 | 2019 | 1 | 0.160 |
Why?
|
| Tunica Intima | 1 | 2019 | 10 | 0.160 |
Why?
|
| Radiography | 3 | 2016 | 522 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2019 | 33 | 0.160 |
Why?
|
| Pleural Effusion | 1 | 2019 | 12 | 0.160 |
Why?
|
| Heart Neoplasms | 1 | 2019 | 11 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2019 | 4 | 0.160 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 1 | 2019 | 3 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 4 | 0.160 |
Why?
|
| Computational Biology | 1 | 2019 | 14 | 0.160 |
Why?
|
| Betacoronavirus | 1 | 2020 | 66 | 0.150 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 14 | 0.150 |
Why?
|
| Hydrazones | 1 | 2019 | 1 | 0.150 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2019 | 16 | 0.150 |
Why?
|
| Pathology, Molecular | 2 | 2016 | 3 | 0.150 |
Why?
|
| Maternal Mortality | 3 | 2014 | 5 | 0.150 |
Why?
|
| Interferon-gamma | 1 | 2019 | 72 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 161 | 0.150 |
Why?
|
| Administration, Oral | 2 | 2020 | 98 | 0.150 |
Why?
|
| Models, Statistical | 1 | 2019 | 113 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2017 | 109 | 0.150 |
Why?
|
| Duodenal Neoplasms | 1 | 2018 | 4 | 0.150 |
Why?
|
| Geriatric Assessment | 1 | 2019 | 159 | 0.150 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2018 | 10 | 0.140 |
Why?
|
| Genotype | 2 | 2016 | 246 | 0.140 |
Why?
|
| Endometrial Stromal Tumors | 1 | 2018 | 1 | 0.140 |
Why?
|
| Oncolytic Viruses | 1 | 2018 | 2 | 0.140 |
Why?
|
| Oncolytic Virotherapy | 1 | 2018 | 3 | 0.140 |
Why?
|
| Breast | 3 | 2007 | 23 | 0.140 |
Why?
|
| Peritoneal Neoplasms | 1 | 2018 | 10 | 0.140 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 26 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2018 | 42 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 2 | 2014 | 14 | 0.140 |
Why?
|
| Early Diagnosis | 2 | 2014 | 48 | 0.140 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2017 | 4 | 0.140 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 431 | 0.140 |
Why?
|
| Desmoplastic Small Round Cell Tumor | 1 | 2017 | 1 | 0.140 |
Why?
|
| Smooth Muscle Tumor | 1 | 2017 | 1 | 0.140 |
Why?
|
| Twist-Related Protein 1 | 1 | 2017 | 3 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 88 | 0.130 |
Why?
|
| Embolization, Therapeutic | 1 | 2017 | 53 | 0.130 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 9 | 0.130 |
Why?
|
| History, 18th Century | 1 | 2016 | 4 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2016 | 18 | 0.130 |
Why?
|
| Achievement | 1 | 2016 | 7 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 35 | 0.130 |
Why?
|
| Gene Duplication | 1 | 2016 | 4 | 0.130 |
Why?
|
| Sex Factors | 1 | 2018 | 380 | 0.130 |
Why?
|
| Research | 1 | 2016 | 34 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2016 | 6 | 0.130 |
Why?
|
| Sequence Deletion | 1 | 2016 | 16 | 0.130 |
Why?
|
| Perioperative Care | 1 | 2016 | 42 | 0.130 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 269 | 0.130 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 103 | 0.130 |
Why?
|
| Propranolol | 1 | 2016 | 4 | 0.120 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 50 | 0.120 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 6 | 0.120 |
Why?
|
| Placebos | 3 | 2021 | 63 | 0.120 |
Why?
|
| Receptors, Progesterone | 3 | 2010 | 26 | 0.110 |
Why?
|
| Risk Factors | 3 | 2021 | 1955 | 0.110 |
Why?
|
| Maternal Welfare | 1 | 2014 | 2 | 0.110 |
Why?
|
| Prenatal Care | 1 | 2014 | 5 | 0.110 |
Why?
|
| Preventive Medicine | 1 | 2014 | 5 | 0.110 |
Why?
|
| Maternal Death | 1 | 2014 | 1 | 0.110 |
Why?
|
| Early Medical Intervention | 1 | 2014 | 13 | 0.110 |
Why?
|
| Confidence Intervals | 1 | 2014 | 75 | 0.110 |
Why?
|
| Time-to-Treatment | 1 | 2014 | 28 | 0.110 |
Why?
|
| Patient Safety | 1 | 2014 | 32 | 0.110 |
Why?
|
| Analysis of Variance | 1 | 2014 | 227 | 0.110 |
Why?
|
| Niacinamide | 1 | 2013 | 4 | 0.110 |
Why?
|
| Genetic Variation | 1 | 2014 | 66 | 0.100 |
Why?
|
| Area Under Curve | 1 | 2013 | 59 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 120 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2017 | 67 | 0.100 |
Why?
|
| Antigens, Surface | 1 | 2012 | 13 | 0.090 |
Why?
|
| Azacitidine | 1 | 2012 | 11 | 0.090 |
Why?
|
| Cause of Death | 1 | 2012 | 49 | 0.090 |
Why?
|
| Chondrosarcoma | 1 | 2012 | 37 | 0.090 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 46 | 0.090 |
Why?
|
| Adjuvants, Immunologic | 2 | 2022 | 14 | 0.090 |
Why?
|
| Europe | 2 | 2021 | 48 | 0.090 |
Why?
|
| London | 1 | 2010 | 2 | 0.090 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2010 | 3 | 0.090 |
Why?
|
| Cytoplasm | 1 | 2010 | 33 | 0.090 |
Why?
|
| Patient Dropouts | 1 | 2010 | 24 | 0.090 |
Why?
|
| Hospitals, Public | 1 | 2010 | 21 | 0.090 |
Why?
|
| Ribonuclease III | 1 | 2010 | 2 | 0.080 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2010 | 4 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2010 | 69 | 0.080 |
Why?
|
| Microscopy, Fluorescence | 2 | 2007 | 68 | 0.080 |
Why?
|
| Abdominal Neoplasms | 1 | 2010 | 16 | 0.080 |
Why?
|
| Predictive Value of Tests | 2 | 2009 | 432 | 0.080 |
Why?
|
| Tumor Burden | 2 | 2021 | 23 | 0.080 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2010 | 4 | 0.080 |
Why?
|
| International Agencies | 2 | 2021 | 4 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2010 | 37 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2010 | 21 | 0.080 |
Why?
|
| Netherlands | 2 | 2020 | 25 | 0.080 |
Why?
|
| Mastectomy | 2 | 2006 | 34 | 0.080 |
Why?
|
| Immunophenotyping | 3 | 2019 | 28 | 0.080 |
Why?
|
| Child, Preschool | 3 | 2021 | 561 | 0.070 |
Why?
|
| Chelating Agents | 1 | 2008 | 13 | 0.070 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 3 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2009 | 217 | 0.070 |
Why?
|
| Bone Marrow | 1 | 2008 | 61 | 0.070 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 84 | 0.070 |
Why?
|
| Tissue Array Analysis | 4 | 2010 | 8 | 0.070 |
Why?
|
| Logistic Models | 1 | 2009 | 350 | 0.070 |
Why?
|
| Caveolin 2 | 1 | 2007 | 1 | 0.070 |
Why?
|
| Fatigue | 2 | 2018 | 46 | 0.070 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2007 | 3 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2008 | 127 | 0.070 |
Why?
|
| Caveolin 1 | 1 | 2007 | 10 | 0.070 |
Why?
|
| Genes, myc | 1 | 2006 | 8 | 0.070 |
Why?
|
| Interferons | 1 | 2006 | 9 | 0.060 |
Why?
|
| Stilbenes | 1 | 2006 | 6 | 0.060 |
Why?
|
| Aromatase Inhibitors | 1 | 2006 | 9 | 0.060 |
Why?
|
| Tretinoin | 1 | 2006 | 15 | 0.060 |
Why?
|
| Arsenicals | 1 | 2006 | 11 | 0.060 |
Why?
|
| Oxides | 1 | 2006 | 13 | 0.060 |
Why?
|
| Trastuzumab | 1 | 2006 | 26 | 0.060 |
Why?
|
| Interleukin-2 | 1 | 2006 | 22 | 0.060 |
Why?
|
| ErbB Receptors | 1 | 2006 | 53 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2006 | 5 | 0.060 |
Why?
|
| Carcinoma | 1 | 2007 | 67 | 0.060 |
Why?
|
| Receptors, Growth Factor | 1 | 2006 | 3 | 0.060 |
Why?
|
| Fibroblasts | 2 | 2020 | 50 | 0.060 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2005 | 1 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2006 | 126 | 0.060 |
Why?
|
| Myeloproliferative Disorders | 1 | 2005 | 4 | 0.060 |
Why?
|
| Daunorubicin | 1 | 2005 | 5 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2005 | 89 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2019 | 81 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2005 | 373 | 0.050 |
Why?
|
| Pregnancy | 2 | 2014 | 308 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 7 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2022 | 50 | 0.050 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2021 | 1 | 0.050 |
Why?
|
| Extremities | 1 | 2021 | 24 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2021 | 12 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2021 | 1 | 0.050 |
Why?
|
| Vaccination | 1 | 2021 | 24 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2021 | 33 | 0.050 |
Why?
|
| Asia | 1 | 2021 | 8 | 0.050 |
Why?
|
| Australia | 1 | 2021 | 21 | 0.050 |
Why?
|
| STAT6 Transcription Factor | 1 | 2021 | 10 | 0.040 |
Why?
|
| North America | 1 | 2021 | 31 | 0.040 |
Why?
|
| Connective Tissue | 1 | 2021 | 19 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2021 | 6 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 29 | 0.040 |
Why?
|
| Anastomotic Leak | 1 | 2021 | 6 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2021 | 30 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 64 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2021 | 125 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 81 | 0.040 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2021 | 62 | 0.040 |
Why?
|
| Morpholines | 1 | 2020 | 14 | 0.040 |
Why?
|
| Biphenyl Compounds | 1 | 2020 | 5 | 0.040 |
Why?
|
| Toe Phalanges | 1 | 2020 | 1 | 0.040 |
Why?
|
| Thigh | 1 | 2020 | 26 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 15 | 0.040 |
Why?
|
| International Cooperation | 1 | 2020 | 14 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 34 | 0.040 |
Why?
|
| Phenotype | 2 | 2014 | 255 | 0.040 |
Why?
|
| United States | 2 | 2016 | 1741 | 0.040 |
Why?
|
| Vascular Surgical Procedures | 1 | 2020 | 22 | 0.040 |
Why?
|
| Infant | 1 | 2021 | 478 | 0.040 |
Why?
|
| Blood Loss, Surgical | 1 | 2020 | 53 | 0.040 |
Why?
|
| Operative Time | 1 | 2020 | 82 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2021 | 526 | 0.040 |
Why?
|
| Everolimus | 1 | 2019 | 3 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 16 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2019 | 38 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2019 | 34 | 0.040 |
Why?
|
| Calcinosis | 1 | 2019 | 43 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2019 | 24 | 0.040 |
Why?
|
| Dogs | 1 | 2019 | 137 | 0.040 |
Why?
|
| Incidence | 1 | 2021 | 618 | 0.040 |
Why?
|
| England | 1 | 2018 | 9 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 2 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 10 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1038 | 0.040 |
Why?
|
| Empathy | 1 | 2018 | 32 | 0.040 |
Why?
|
| Focus Groups | 1 | 2018 | 79 | 0.040 |
Why?
|
| Co-Repressor Proteins | 1 | 2018 | 1 | 0.040 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2018 | 1 | 0.040 |
Why?
|
| Mesentery | 1 | 2018 | 6 | 0.040 |
Why?
|
| Cytokines | 1 | 2019 | 200 | 0.040 |
Why?
|
| Colectomy | 1 | 2018 | 20 | 0.040 |
Why?
|
| Hysterectomy | 1 | 2018 | 24 | 0.040 |
Why?
|
| Alopecia | 1 | 2017 | 2 | 0.030 |
Why?
|
| Neutropenia | 1 | 2017 | 16 | 0.030 |
Why?
|
| Nausea | 1 | 2017 | 24 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 18 | 0.030 |
Why?
|
| Stomatitis | 1 | 2017 | 1 | 0.030 |
Why?
|
| Leukopenia | 1 | 2017 | 7 | 0.030 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2017 | 6 | 0.030 |
Why?
|
| Drug Eruptions | 1 | 2017 | 7 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2017 | 10 | 0.030 |
Why?
|
| Exanthema | 1 | 2017 | 10 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2017 | 13 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2017 | 15 | 0.030 |
Why?
|
| Anemia | 1 | 2017 | 30 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 21 | 0.030 |
Why?
|
| Social Support | 1 | 2018 | 174 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 789 | 0.030 |
Why?
|
| Colon | 1 | 2018 | 110 | 0.030 |
Why?
|
| Pneumonectomy | 1 | 2017 | 71 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2017 | 12 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2016 | 5 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 270 | 0.030 |
Why?
|
| Decision Making | 1 | 2018 | 174 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 512 | 0.030 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2016 | 1 | 0.030 |
Why?
|
| Pericytes | 1 | 2016 | 3 | 0.030 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2016 | 3 | 0.030 |
Why?
|
| Epithelial Cells | 2 | 2007 | 70 | 0.030 |
Why?
|
| Carcinoma, Lobular | 2 | 2007 | 22 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 752 | 0.030 |
Why?
|
| Vincristine | 1 | 2015 | 23 | 0.030 |
Why?
|
| Etoposide | 1 | 2015 | 27 | 0.030 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 94 | 0.030 |
Why?
|
| Pain | 1 | 2018 | 325 | 0.030 |
Why?
|
| Mice | 1 | 2019 | 1224 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2021 | 804 | 0.030 |
Why?
|
| Depression | 1 | 2018 | 368 | 0.030 |
Why?
|
| Patient Selection | 1 | 2016 | 167 | 0.030 |
Why?
|
| Awareness | 1 | 2014 | 37 | 0.030 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 39 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2014 | 8 | 0.030 |
Why?
|
| Population Surveillance | 1 | 2014 | 100 | 0.030 |
Why?
|
| Critical Illness | 1 | 2014 | 98 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2013 | 62 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2014 | 110 | 0.030 |
Why?
|
| Maternal Health Services | 1 | 2012 | 1 | 0.020 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 2012 | 3 | 0.020 |
Why?
|
| Antigens | 1 | 2012 | 9 | 0.020 |
Why?
|
| Testis | 1 | 2012 | 9 | 0.020 |
Why?
|
| Program Development | 1 | 2012 | 44 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 11 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2012 | 12 | 0.020 |
Why?
|
| DNA Primers | 1 | 2012 | 50 | 0.020 |
Why?
|
| Epitopes | 1 | 2012 | 39 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 37 | 0.020 |
Why?
|
| Models, Biological | 1 | 2014 | 300 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2011 | 22 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2012 | 102 | 0.020 |
Why?
|
| Illinois | 1 | 2012 | 216 | 0.020 |
Why?
|
| Peptides | 1 | 2012 | 89 | 0.020 |
Why?
|
| Protein Phosphatase 2C | 1 | 2010 | 1 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 25 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 88 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 109 | 0.020 |
Why?
|
| Registries | 1 | 2010 | 153 | 0.020 |
Why?
|
| Adipocytes | 1 | 2007 | 22 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 55 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2007 | 58 | 0.020 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2007 | 3 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2007 | 17 | 0.020 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2007 | 3 | 0.020 |
Why?
|
| Chromogenic Compounds | 1 | 2006 | 4 | 0.020 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2007 | 32 | 0.020 |
Why?
|
| Keratin-14 | 1 | 2006 | 1 | 0.020 |
Why?
|
| Keratins | 1 | 2006 | 2 | 0.020 |
Why?
|
| Keratin-6 | 1 | 2006 | 2 | 0.020 |
Why?
|
| Keratin-5 | 1 | 2006 | 2 | 0.020 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2006 | 5 | 0.020 |
Why?
|
| Receptors, Nerve Growth Factor | 1 | 2006 | 9 | 0.020 |
Why?
|
| Fibroadenoma | 1 | 2006 | 6 | 0.020 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2006 | 12 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 578 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 574 | 0.010 |
Why?
|